Yale University

Effectiveness of Simeprevir plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients with HCV Genotype 1 Infection.

TitleEffectiveness of Simeprevir plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients with HCV Genotype 1 Infection.
Publication TypeJournal Article
Year of Publication2015
AuthorsSulkowski, M. S., H. E. Vargas, A. M. Di Bisceglie, P. A. Kuo, K. R. Reddy, J. K. Lim, G. Morelli, J. M. Darling, J. J. Feld, R. S. Brown, L. M. Frazier, T. G. Stewart, M. W. Fried, D. R. Nelson, and I. M. Jacobson
Corporate AuthorsHCV-TARGET study group
JournalGastroenterology
Date Published2015 Oct 21
ISSN1528-0012
AbstractThe interferon-free regimen of simeprevir plus sofosbuvir was recommended by professional guidelines for certain patients with hepatitis C virus (HCV) genotype 1 infection based on the findings of a phase 2 trial. We aimed to evaluate the safety and efficacy of this regimen in clinical practice settings in North America.
DOI10.1053/j.gastro.2015.10.013
Alternate JournalGastroenterology

External Links